Trial Profile
NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With Programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Inhibitors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Brachyury peptide vaccine (Primary) ; CST 101 (Primary) ; ETBX 011 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; Inbakicept (Primary) ; Avelumab; Bevacizumab; Capecitabine; Cisplatin; Cyclophosphamide; Fluorouracil; Folinic acid; Fulvestrant; Nivolumab; Omega-3-acid ethyl esters; Oxaliplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NantKwest
- 23 Aug 2019 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
- 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.